NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $113.04M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 1.39M
Average 1.27M
Returns on capital
NRx Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
179.6%
avg -35.5%
ROIC
106.0%
avg 72.4%
ROA
-220.9%
avg -391.0%
Analysis
ROE is currently the strongest return metric at 179.6% versus its period average of -35.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jonathan C. Javitt | Co-Founder, Chairman & CEO | USD 846.77K | 69 | 150.00K | 0.87% |
Michael S. Abrams | CFO & Treasurer | USD 363.08K | 56 | 75.00K | 0.43% |
Riccardo Panicucci | Chief Manufacturing & Technology Officer | USD 240K | 64 | — | — |
Dennis K. McBride | Chief Strategy Officer & Director | USD 38.46K | 71 | — | — |
Hervé Perron | Chief Scientist | — | 67 | — | — |
Philip T. Lavin | Chief Methodologist | — | 79 | — | — |
Glenn Tyson | Chief Commercial Officer | — | — | — | — |
Joseph Casper | Chief Operating Officer | — | 75 | — | — |
Michael Taylor | Chief Development Officer & Director | — | 51 | — | — |
Joshua C. Brown | Chief Medical Innovation Officer | — | — | — | — |
Suzanne Messere | Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 28, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +278.2% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +278.2% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does NRx Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about NRXP's management, answered from reported figures.
Who manages NRXP?
NRx Pharmaceuticals, Inc. (NRXP) lists 11 active executives. The top listed executive is Dennis K. McBride, Chief Strategy Officer & Director.
Are NRXP insiders buying or selling?
Recent insider activity shows net buying of $20.54M.
Continue the stock analysis
Jump to another research area for this company.